The COVAX Facility will channel funds provided by middle- to high-income countries involved in the program toward a number of pharmaceutical companies that are working to develop vaccines, which will also be provided to low-income nations.
The deal is the latest example of countries rushing to secure access to vaccines, and comes weeks after Canada signed separate deals with Pfizer Inc and Moderna Inc.
"That's why the government of Canada has moved forward on signing agreements with a broad range of vaccine developers of researchers around the world, so that, regardless of who ends up developing the vaccine first, Canadians will have the opportunity to benefit from that vaccine".
It is also openly saying that it would donate to poorer countries surplus vaccines that it acquires through its scheme, in what seems to replicate COVAX's core function.
"The most recent vaccine tests show promising results, if one is successful Canadians will have access to the doses", Trudeau said. By July, the United States communicated its intent to withdraw from the WHO.
Getting a coronavirus vaccine from manufacturing sites to some parts of the world with rural populations and unreliable electricity supply will be an vast challenge, given the need to store some vials at temperatures as low as minus 80 degrees Celsius (-112 Fahrenheit), Deutsche Post (DPWGn.DE) warned on Tuesday.
U.S. to partially lift arms embargo on Cyprus
Ankara is also carrying out military exercises in the Eastern Mediterranean, off Iskenderun on the southern coast of Turkey. Oktay said Wednesday that Turkey and the Turkish Cypriot state are "aware of the games that are being played against them".
"The vaccination did not affect them in any way", he added.
The Trump administration said Tuesday that it will not work with an worldwide cooperative effort to develop and distribute a COVID-19 vaccine because it does not want to be constrained by multilateral groups like the World Health Organization. It now has nine COVID-19 vaccine candidates in its portfolio employing a range of different technologies and scientific approaches.
Trudeau also announced the government would be spending $126 million to expand the bio-manufacturing facility at the National Research Council in Montreal, with a projected deadline of mid-2021. Novavax previously released findings from the study that said the vaccine candidate induced immune responses and was well-tolerated, but more more data from the study was published Wednesday in The New England Journal of Medicine.
Its vaccine, which has been given to patients in two doses, is in Phase 2 of multiple human trials.
This leaves Richard Hatchett, the head of the Coalition for Epidemic Preparedness Innovations (CEPI), anxious as his job is to ensure that future vaccines against COVID-19 will be shared on an equitable basis around the world. Trudeau announced that partnership in May, but China never approved shipments of the vaccine to be exported to Canada and the NRC killed the deal last week. The new facility is meant to produce up to two million doses of vaccine a month by the end of next summer.